Reparixin L-lysine salt

Key Product Details

Product Description

Reparixin L-lysine salt is a potent and noncompetitive CXCR1 and CXCR2 allosteric antagonist (IC₅₀ = 1 nM for inhibition of CXCL8-induced human polymorphonuclear cell migration). Also inhibits migration of rodent neutrophils induced by CXCL1, CXCL2, CXCL8 and CINC-1. Inhibits vascular permeability and neutrophil recruitment in in vivo models of mild and severe ischemia/reperfusion injury. Also selectively depletes cancer stem cells in human breast cancer cell lines and xenograft models.

Product Specifications for Reparixin L-lysine salt

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Reparixin L-lysine salt

The following data is based on the product molecular weight 429.58.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.66 mL	23.28 mL	46.56 mL
2.5 mM	0.93 mL	4.66 mL	9.31 mL
5 mM	0.47 mL	2.33 mL	4.66 mL
25 mM	0.09 mL	0.47 mL	0.93 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Souza Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br.J.Pharmacol. 2004 PMID: 15302676
• Ginestier CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J.Clin.Invest. 2010 PMID: 20051626
• Bertini Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc.Natl.Acad.Sci.U.S.A. 2004 PMID: 15282370

Product Documents for Reparixin L-lysine salt